ClinicalTrials.gg
CompletedNCT01837641Updated Oct 4, 2024Results posted

A Study of LY3002813 in Participants With Alzheimer's Disease

A Phase 1 interventional study of LY3002813-IV and LY3002813-SC in Alzheimer Disease, sponsored by Eli Lilly and Company. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.

Enrollment
12th of 15
63 · median 240
Started
2013
the only one that year
Phase 1
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
12 of 15
Eli Lilly and Company

Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 12th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 1, and was the 1st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About donanemab

donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing donanemab in Alzheimer Disease, or all of them as a file.
02

Study summary

The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813. Study participants will be healthy or will have mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.

There will be seven groups of study participants. Five groups will receive a single dose of LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo given as an injection into a vein. Approximately 12 weeks will pass between the single dose and the first multiple dose. One group of participants will receive a single dose of LY3002813 given as an injection under the skin. One group of participants will receive a single dose of LY3002813 given as an injection into a vein.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Participants:

    • Overtly healthy males, as determined by medical history and physical examination, willing to use a reliable method of and will not donate sperm during the study
    • Between 18 to 40 years old.
    • (BMI) of between 18.0 and 30.0 kilogram per meter square (kg/m\^2), inclusive
  • Participants with Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or AD:

    • Present with mild cognitive impairment (MCI) due to AD or mild-to-moderate AD
    • Men or nonfertile women, at least 50 years of age. Nonfertile is defined as hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year
    • Have a caregiver/study informant who provides a separate written to participate
    • Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator
    • Positive florbetapir scan

Exclusion criteria

Exclusion Criteria:

-Healthy Participants: Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, immunological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data

  • Participants with Mild Cognitive Impairment Due to AD or AD:

    • Do not have a reliable caregiver/study informant who is in frequent contact with the participant, who will accompany the participant to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications
    • Are being monitored for radiation due to occupational exposure to ionized radiation, or exposure to ionizing radiation within last 12 months from an study
    • History within the past 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen post resection
  • All Participants:

    • History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, or stroke or epilepsy
    • Have any for magnetic resonance imaging (MRI) studies, including claustrophobia, the presence of contraindicated metal (ferromagnetic) implants, cardiac pacemaker
    • Have allergies to humanized monoclonal antibodies, including proteins and diphenhydramine, epinephrine, and methylprednisolone
    • Have gamma globulin therapy within the last year
    • Previously dosed in any other study investigating active immunization against amyloid beta (Aβ)
    • Previously dosed in any other study investigating passive immunization against Aβ within the last 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg

    0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)

    Biological: LY3002813-IV

  • Experimental
    LY3002813-Single then multiple 0.3 mg/kg

    0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV

    Biological: LY3002813-IV

  • Experimental
    LY3002813-Single 1 mg/kg in Healthy Participants

    1 mg/kg single dose LY3002813 given once by IV infusion.

    Biological: LY3002813-IV

  • Experimental
    LY3002813-Single then multiple 1 mg/kg

    1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV

    Biological: LY3002813-IV

  • Experimental
    LY3002813-Single then multiple 3 mg/kg

    3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV

    Biological: LY3002813-IV

  • Experimental
    LY3002813-Single then multiple 10 mg/kg

    10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV

    Biological: LY3002813-IV

  • Placebo comparator
    Placebo-Single then multiple

    Placebo given once, then every 4 weeks for up to 16 weeks IV

    Drug: Placebo-IV

  • Experimental
    LY3002813-SC

    Up to 3 mg/kg LY3002813 given once subcutaneously (SC)

    Biological: LY3002813-SC

  • Experimental
    LY3002813-IV

    Up to 3mg/kg LY3002813 given once intravenously (IV)

    Biological: LY3002813-IV

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Data presented are the number of participants who experienced SAEs which were considered to be related to study treatment by the investigator while on treatment and during the follow-up. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.

    Time frame: Day 1 up to Day 253

Secondary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813

    Maximum Concentration (Cmax) of LY3002813 after the first dose was evaluated.

    Time frame: Pre-dose, end of infusion for IV or 1h post injection for SC, 3, 24, 72, 96(SC), 120(SC), 144(SC), 168, 336, 504, 672, 1008, 1344, 1680 and 2016 hours (h) post-dose

  2. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY3002813

    Area Under the Concentration Versus Time Curve From Time Zero to Infinity \[AUC(0-∞)\] of LY3002813 after the first dose was evaluated.

    Time frame: Pre-dose, end of infusion for IV or 1h post injection for SC, 3, 24, 72, 96(SC), 120(SC), 144(SC), 168, 336, 504, 672, 1008, 1344, 1680 and 2016h post-dose

07

Results

Posted Oct 4, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SC
Started1247691168
Received at least 1 dose of study drug1247691168
Completed114768958
Not completed10001210
Withdrew: Sponsor decision10000100
Withdrew: Adverse event00000100
Withdrew: Withdrawal by subject00001010

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Data presented are the number of participants who experienced SAEs which were considered to be related to study treatment by the investigator while on treatment and during the follow-up. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.

Time frame:
Day 1 up to Day 253
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsPlacebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SC
Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration10201000
SecondaryPharmacokinetics: Maximum Concentration (Cmax) of LY3002813

Maximum Concentration (Cmax) of LY3002813 after the first dose was evaluated.

Time frame:
Pre-dose, end of infusion for IV or 1h post injection for SC, 3, 24, 72, 96(SC), 120(SC), 144(SC), 168, 336, 504, 672, 1008, 1344, 1680 and 2016 hours (h) post-dose
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813
microgram per milliliter (μg/mL)0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SC
Pharmacokinetics: Maximum Concentration (Cmax) of LY30028132.90 ± 355.99 ± 7731.5 ± 2921.7 ± 2171.6 ± 24218 ± 1612.0 ± 34
SecondaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY3002813

Area Under the Concentration Versus Time Curve From Time Zero to Infinity \[AUC(0-∞)\] of LY3002813 after the first dose was evaluated.

Time frame:
Pre-dose, end of infusion for IV or 1h post injection for SC, 3, 24, 72, 96(SC), 120(SC), 144(SC), 168, 336, 504, 672, 1008, 1344, 1680 and 2016h post-dose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY3002813
microgram*day per milliliter (μg*day/mL)0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SC
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY30028137.94 ± 3226.3 ± 3391.6 ± 1779.9 ± 26263 ± 191140 ± 39157 ± 41

Adverse events

Collected over Day 1 up to Day 253. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo IV—1/12 (8.3%)8/12 (66.7%)
0.1 mg/kg / 0.3 mg/kg LY3002813 IV—0/4 (0%)3/4 (75%)
0.3 mg/kg LY3002813 IV—2/7 (28.6%)4/7 (57.1%)
1 mg/kg LY3002813 IV: Healthy Participants—0/6 (0%)3/6 (50%)
1 mg/kg LY3002813 IV—1/9 (11.1%)6/9 (66.7%)
3 mg/kg LY3002813 IV—0/11 (0%)7/11 (63.6%)
10 mg/kg LY3002813 IV—0/6 (0%)2/6 (33.3%)
3 mg/kg LY3002813 SC—0/8 (0%)4/8 (50%)
Most frequent serious events
Most frequent serious events
EventPlacebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SC
Urinary tract infectionInfections and infestations0/120/41/70/60/90/110/60/8
Hip fractureInjury, poisoning and procedural complications0/120/41/70/60/90/110/60/8
Cervical vertebral fractureInjury, poisoning and procedural complications0/120/40/70/61/90/110/60/8
Non-cardiac chest painGeneral disorders1/120/40/70/60/90/110/60/8
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPlacebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SC
Infusion related reactionInjury, poisoning and procedural complications0/120/41/70/62/93/110/60/8
DiarrhoeaGastrointestinal disorders0/121/41/70/60/90/110/60/8
Chest discomfortGeneral disorders0/121/40/70/60/90/110/60/8
ArthralgiaMusculoskeletal and connective tissue disorders0/121/40/70/60/90/110/60/8
ParkinsonismNervous system disorders0/121/40/70/60/90/110/60/8
ApathyPsychiatric disorders0/121/40/70/60/90/110/60/8
Urinary retentionRenal and urinary disorders0/121/40/70/60/90/110/60/8
FallInjury, poisoning and procedural complications0/120/40/70/61/92/110/61/8
NauseaGastrointestinal disorders0/120/40/71/60/91/110/60/8
VomitingGastrointestinal disorders0/120/40/71/60/90/110/60/8

Baseline characteristics

All enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SCTotal
Mean76.8 ± 4.971.3 ± 11.675.0 ± 8.425.8 ± 3.374.7 ± 9.373.0 ± 8.872.3 ± 10.774.5 ± 9.569.7 ± 16.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SCTotal
Female7340482533
Male5136534330
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SCTotal
Hispanic or Latino000210104
Not Hispanic or Latino124748115859
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SCTotal
American Indian or Alaska Native000000000
Asian5230342221
Native Hawaiian or Other Pacific Islander000100001
Black or African American101001003
White6235664638
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(Participants)Placebo IV0.1 mg/kg / 0.3 mg/kg LY3002813 IV0.3 mg/kg LY3002813 IV1 mg/kg LY3002813 IV: Healthy Participants1 mg/kg LY3002813 IV3 mg/kg LY3002813 IV10 mg/kg LY3002813 IV3 mg/kg LY3002813 SCTotal
United States8246674643
Japan4230342220
08

Study locations

6 sites
  • Collaborative Neuroscience Network - CNS
    Long Beach, California 90806, United States
  • Compass Research
    Orlando, Florida 32806, United States
  • Atlanta Center of Medical Research
    Atlanta, Georgia 30308, United States
  • PRAHealthSciences
    Salt Lake City, Utah 84106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sumida-Ku, 130-0004, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 162-0053, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Aug 2016, 39 months.

Results were first posted in Oct 2024, 8 years 1 month after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 39 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2013
First posted
Apr 23, 2013
StartActual
May 3, 2013
Primary completionActual
Aug 24, 2016
CompletionActual
Aug 24, 2016
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01837641
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
May 3, 2013
Primary completion
Aug 24, 2016
Completion
Aug 24, 2016
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion